APA (7th ed.) Citation

S, S., UG, G., G, S., C, H., JWF, C., JD, K., . . . F, L. (2025). Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer in a Swedish setting. Frontiers in oncology, 15, 1556881. https://doi.org/10.3389/fonc.2025.1556881

Chicago Style (17th ed.) Citation

S, Saha, Gerdtham UG, Sjödahl G, Häggström C, Catto JWF, Kelly JD, Ullén A, Holmberg L, and Liedberg F. "Cost-effectiveness of De-escalated Molecular Subtype Dependent Use of Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer in a Swedish Setting." Frontiers in Oncology 15 (2025): 1556881. https://doi.org/10.3389/fonc.2025.1556881.

MLA (9th ed.) Citation

S, Saha, et al. "Cost-effectiveness of De-escalated Molecular Subtype Dependent Use of Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer in a Swedish Setting." Frontiers in Oncology, vol. 15, 2025, p. 1556881, https://doi.org/10.3389/fonc.2025.1556881.